Jeffrey William Henderson Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $53.76 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The business has a fifty day simple moving average of $50.10 and a 200 day simple moving average of $54.00. The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Analysts Set New Price Targets

A number of research firms have recently commented on HALO. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research report on Monday, December 30th. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB increased its position in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Boston Trust Walden Corp grew its stake in Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after buying an additional 239,321 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock worth $36,449,000 after purchasing an additional 191,030 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.